Market Research Report
Drugs for Treating Mental Disorders: Technologies and Global Markets
|Published by||BCC Research||Product code||208650|
|Published||Content info||180 Pages
Delivery time: 1-2 business days
|Drugs for Treating Mental Disorders: Technologies and Global Markets|
|Published: February 3, 2014||Content info: 180 Pages||
The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.
The objective and tenacity in conducting this study is to provide an overview of the current and future characteristics of the global market for psychiatric drugs. The awareness and better understanding of mental disorders across the globe is on the rise. Globally, approximately 120 million people have been diagnosed with mental disorders and are taking psychiatric drugs as "treatment." The key objective is to present a comprehensive analysis and future direction of psychiatric drugs as a treatment for various mental disorders.
This report explores present and future strategies within the different classes of psychiatric drugs market, which includes antidepressants, antipsychotics, antianxiety (anxiolytics), childhood and adolescent mental disorders therapeutics, cognitive disorders therapeutics, sleep disorders therapeutics and substance abuse drugs. The growth of the market, the setbacks and the needs of the market are discussed in this report. The classifications, comparisons and usage of these types of medications in various mental disorders are discussed in this report.
A detailed analysis of the psychiatric drugs industry has been conducted. Revenues are broken down by the region and its types. Sales figures are estimated for the five-year period from 2013 through 2018.
The report also covers the prevalence of mental disorders, new developments in psychiatric drugs, regulatory aspects of these medications, and significant patents and their allotments in each category.
The amount of mental illness medications have continued to grow over the past decade. There is a big increase in the use of powerful antipsychotic drugs across all ages in recent years. Wide research in the field of psychiatric drugs has revealed their ability to provide therapeutic treatments for various mental disorders. Pharmaceutical industries have now begun to explore the therapeutic use of psychiatric medications in their productions and processes. This has led to a continuous market for them.
R&D spending, along with increasing competition, patent expiries, new technologies and public awareness of mental disorders are directing this market. The advancements, new product launches and changing lifestyles have influenced the market to grow in the near future. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/ technology in light of the new technologies, growing competition and changing customer needs.
This study contributes to the areas of market growth in psychiatric drug manufacturers and users. Pharmaceutical companies, research institutes and physicians will find this study to be of interest.
The scope of this study encompasses psychiatric drugs in pharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technology, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes countries like India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand, etc.